FTC endorses greater access to affordable biosimilars

FTC backs FDA's proposals to streamline approval process for interchangeable biosimilars | Move aims to lower prescription drug costs and expand access to critical treatments | FTC emphasises the new guidance could create competition in the biologics market and save US healthcare billions of dollars.